공시 • Nov 10
Simcere Pharmaceutical Group Limited Announces Executive Changes
Simcere Pharmaceutical Group Limited announcrd that, Mr. Bao Jun has tendered his resignation as a joint company secretary of the Company (the "Joint Company Secretary"), an authorized representative of the Company for the purpose of Rule 3.05 of the Listing Rules and the secretary to the Board, with effect from November 9, 2022 due to his personal career development. The Board further announces that Mr. Wan Yushan, currently an executive Director and the chief financial officer of the Company, has been concurrently appointed as a Joint Company Secretary and the secretary to the Board to replace Mr. Bao with effect from November 9, 2022. Ms. Mak Po Man Cherie, who meets the requirements under Rules 3.28 and 8.17 of the Listing Rules, currently the other Joint Company Secretary, will continue to act as a Joint Company Secretary and will continue to perform and discharge the duties of a company secretary under the Listing Rules. The Board further announces that Mr. Tang Renhong, currently an executive Director and the Co-CEO of the Company has been appointed as an Authorized Representative of theCompany in accordance with Rule 3.05 of the Listing Rules with effect from November 9, 2022. Mr. Wan, aged 51, is an executive Director and the chief financial officer of the Company. He is primarily responsible for the financial, legal and compliance management, formulating financial strategies and in charge of the process and information business of the Group. Mr. Wan has over 20 years of experience with the Group where he has accumulated knowledge and skills required in the financial management of the Group. Mr. Wan joined the Group in May 2000 and has assumed various positions successively since then, including the financial controller, general manager of financial department, vice president and chief financial officer. On November 19, 2019, Mr. Wan was officially appointed as an executive Director and the chief financial officer of the Company. He has also been the director of several subsidiaries of the Company including, among others, Hainan Simcere Pharmaceutical Co. Ltd. since July 2011, Shandong Simcere Biopharmaceutical Co. Ltd. since August 2017 and Simcere Pharmaceutical Co. Ltd. since July 2017. Mr. Wan obtained a bachelor's degree in biochemistry from Nanjing University in June 1992 and a master's degree in management (majoring in accounting) from Nanjing University in June 1999. Mr. Wan was admitted as a non-practicing member of Jiangsu Institute Certified Public Accountants in November 2009. Ms. Mak was appointed as one of the joint company secretaries on September 17, 2020, which took effect on the same day. Ms. Mak is the vice president of SWCS Corporate Services Group (Hong Kong) Limited. She has worked for various professional firms and listed companies in Hong Kong, with over 18 years of experience in the fields of audit, accounting, corporate finance, compliance and corporate secretarial. Ms. Mak obtained a Master of Corporate Governance degree from The Hong Kong Polytechnic University in 2017. She has been admitted as an associate member of The Hong Kong Chartered Governance Institute and The Chartered Governance Institute in the United Kingdom in 2017, a member of the Hong Kong Institute of Certified Public Accountants in 2003 and a fellow member of the Association of Chartered Certified Accountants in 2006. Mr. Tang, aged 42, is an executive Director and the Co-CEO of the Company. He is primarily responsible for the overall leading of the Group's research and development affairs. Mr. Tang hasnearly 12 years of experience in pharmaceutical research and development and management of pharmaceutical companies. Mr. Tang joined the Group acting as the vice president in May 2019. He was officially appointed as an executive Director and the vice president of the Company on November 19, 2019 and further appointed as the senior vice president, the executive vice president and the Co-CEO of the Company on June 1, 2020, March 31, 2021 and May 25, 2022, respectively. Prior to that, he served as the vice general manager of Shanghai Shengdi Pharmaceutical Co. Ltd. from September 2017 to May 2019. From September 2013 to August 2017, Mr. Tang worked as the associate director of China Innovation Center of Astrazeneca Investment (China) Co. Ltd. Before that, he worked at the Novo Nordisk Research Centre China from June 2009 to September 2013 with the last position there being the head of department. At the beginning of his career, he was a postdoctoral researcher at the University of California, San Francisco from April 2007 to May 2009. Mr. Tang obtained a bachelor's degree in biotechnology from Shanghai Jiao Tong University in July 2002 and a Ph.D. in molecular cell biology from Nanyang Technological University in April 2007.